Viropharma, Inc. (VPHM) Tops Q3 EPS by 23c; Guides FY11 Cinryze Net Sales
Tweet Send to a FriendGet Alerts VPHM Hot Sheet
Price: $26.44 +1.30%
EPS Growth %: -2.3%
Financial Fact:
Research and development: 17.2M
Today's EPS Names:
TARO, SENEA, UQM, More
EPS Growth %: -2.3%
Financial Fact:
Research and development: 17.2M
Today's EPS Names:
TARO, SENEA, UQM, More
Trade VPHM Now!
Viropharma, Inc. (NASDAQ: VPHM) reported Q3 EPS of $0.56, $0.23 better than the analyst estimate of $0.33. Revenue for the quarter came in at $143 million versus the consensus estimate of $129.47 million.
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 5c; Issues Outlook
- Nordson Corp (NDSN) Reports In-Line Q2 EPS, Q3 Guidance Falls Short
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
